Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Novel Biomarkers (TIMP-2 and IGFBP7) of Tubular Renal Cell Damage for the Prediction of the Cardiac Surgery Associated Acute Kidney Injury (CSA-AKI) - A Feasibility Study

NCT02054546 is registered in ClinicalTrials.gov with University Hospital, Basel, Switzerland as lead sponsor.

NCT NCT02054546
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02054546 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Novel Biomarkers (TIMP-2 and IGFBP7) of Tubular Renal Cell Damage for the Prediction of the Cardiac Surgery Associated Acute Kidney Injury (CSA-AKI) - A Feasibility Study
Lead sponsor
University Hospital, Basel, Switzerland
Phase
Observational
Overall status
Completed
Start date
December 31, 2013
Completion date
December 31, 2014
Enrollment
110 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

acute kidney injury